Tissue Customized Platelet-Rich Plasma Removing Inhibitory Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical outcomes of platelet-rich plasma (PRP) treatments for musculoskeletal tissue healing are inconsistent due to unclear mechanisms of action and variations in PRP preparation protocols, which can include inhibitory bioactive components that hinder healing processes such as scarring or fibrosis.
Innovation Solution
A method of preparing a platelet-rich-plasma-derived composition by removing deleterious factors like VEGF, PDGF, TGF-β1, or noggin from activated PRP releasate using affinity-purification reagents, resulting in a composition that promotes tissue growth, repair, or healing without abnormal tissue effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRP is used for tissue healing, then growth factors promote tissue regeneration, but inhibitory bioactive components cause fibrosis and scarring
Solution Approach 1:
The patent extracts and removes specific inhibitory bioactive components (VEGF, PDGF, TGF-β1, noggin) from the PRP composition through affinity-purification reagents, while retaining the beneficial growth factors. This selective extraction resolves the contradiction by eliminating harmful factors without sacrificing the regenerative properties of PRP.
Solution Approach 2:
The patent modifies the biochemical composition parameters of PRP by selectively removing specific bioactive components. This parameter change transforms the PRP from a composition with both beneficial and harmful factors into a customized composition with optimized biological activity for specific tissue types, improving healing outcomes while eliminating fibrosis and scarring.
2Ease of manufacture
If standard PRP preparation protocols are used, then treatment is simple and accessible, but clinical outcomes are inconsistent and mechanism is unclear
Solution Approach 1:
The patent segments the PRP preparation process into distinct functional stages: (1) standard PRP preparation, (2) activation, (3) affinity-purification to remove inhibitory factors, and (4) customization for specific tissue types. This segmentation maintains the simplicity of basic PRP preparation while adding targeted purification steps that ensure consistent and reliable clinical outcomes through standardized protocols.
3Quantity of substance
If multiple bioactive components are present in PRP, then biological activity is enhanced, but variability in preparation protocols creates inconsistent effects
Solution Approach 1:
The patent applies local quality customization by removing specific bioactive components based on the target tissue type. Different PRP compositions are tailored for different tissues (e.g., removing VEGF for cartilage, removing TGF-β1 for muscle), creating standardized compositions with consistent biological properties appropriate for each tissue type, thereby reducing variability while maintaining relevant biological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The customized PRP composition enhances tissue regeneration by reducing inhibitory factors by up to 99.9%, improving muscle, cartilage, and bone healing by minimizing fibrosis, angiogenesis, and scarring, as demonstrated by increased cell proliferation, micro-vessel formation, and reduced collagen deposition.
Implementation Method 1
an affinity-purification reagent comprising a binding reagent specific to, and for binding, a deleterious factor of activated PRP
Data Source
AI summary
Provided herein is a platelet-rich plasma (PRP) product comprising activated PRP releasate in which a deleterious factor that inhibits growth of a target tissue type is removed. The PRP product is useful in growth or regeneration of tissue of the target tissue type, such as muscle, cartilage, or bone. Also provided herein is a method of making a tissue-customized PRP product for growth or repair of a target tissue, such as muscle, cartilage, or bone, comprising removing a deleterious factor for the growth of the target tissue from activated PRP releasate.